Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Left-sided Aspergillus fumigatus endocarditis was established in the guinea pig heart by catheterization and inoculation with conidia via a tributary of the femoral vein. This animal model was used to compare the efficacy of the triazole antifungal agents voriconazole (UK-109,496) and itraconazole. In the prophylaxis experiments, voriconazole at a dosage of 10 mg/kg of body weight given intraperitoneally twice daily prevented A. fumigatus endocarditis in all but 1 animal (11 of 12 animals were cured). Itraconazole did not prevent Aspergillus endocarditis when it was given at the same dosage and by the same route (0 to 12 animals were cured). In the treatment experiments with 10 animals per group, voriconazole at 10, 7.5 and 5 mg/kg given orally twice daily for 7 days produced cure rates of 100, 70 and 0%, respectively. In contrast, itraconazole at 10 mg/kg given orally twice daily did not cure A. fumigatus endocarditis in the guinea pig. It is concluded that voriconazole is highly efficacious in the prevention and treatment of Aspergillus endocarditis in the guinea pig and is superior to itraconazole in these respects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
“Several new antifungal drugs, such as the azoles voriconazole (Pfizer), UR 9825 (Uriach) and Sch 565-92 (Schering-Plough) or derivatives of echinocandins (Eli Lilly, Merck), are under development and in clinical trials, but the results of the trials have not been released (1, 36, 37, 91, 325, 398, 450, 467, 532, 689).”
BackgroundCurrent and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Self-citationEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Gould, F. K., Denning, D. W., Elliott, T. S. J., Foweraker, J., Perry, J. D., Prendergast, B. D., Sandoe, J. A. T., Spry, M. J., & Watkin, R. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr450 · Cited by 593
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 404
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Invasive Aspergillosis in Transplant Recipients
Paterson, D. L., & Singh, N. (1999) · Medicine · doi:10.1097/00005792-199903000-00003 · Cited by 359
THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMAN
Roffey, S. J., Cole, S., Comby, P., Gibson, D., Jezequel, S. G., Nedderman, A. N. R., Smith, D. A., Walker, D. K., & Wood, N. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.731 · Cited by 330
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Kirkpatrick, W. R., Perea, S., Coco, B. J., & Patterson, T. F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2564-2568.2002 · Cited by 282
Sutton, D. A., Sanche, S. E., Revankar, S. G., Fothergill, A. W., & Rinaldi, M. G. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.7.2343-2345.1999 · Cited by 255
Desoubeaux, G., & Cray, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00841 · Cited by 55
“Using an interesting endocarditis model in guinea pigs (Martin et al., 1997), some investigators were able to highlight the superiority of voriconazole over itraconazole to cure aspergillosis.”
BackgroundInfluentialLaskaris, P., Atrouni, A., Calera, J. A., d'Enfert, C., Munier-Lehmann, H., Cavaillon, J.-M., Latgé, J.-P., & Ibrahim-Granet, O. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-16 · Cited by 37
Aspergillus fumigatus and Aspergillosis
(2008) · doi:10.1128/9781555815523 · Cited by 31
Metadata
- Authors
- Martin, M. V., Yates, J., & Hitchcock, C. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-01
- Volume
- 41
- Issue
- 1
- Pages
- 13-16
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2125636331
- Cited by
- 110
- References
- 1
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.